Clinical Trials Logo

Advanced Non-squamous NSCLC clinical trials

View clinical trials related to Advanced Non-squamous NSCLC.

Filter by:
  • None
  • Page 1

NCT ID: NCT04670913 Recruiting - Clinical trials for Advanced Non Squamous NSCLC

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Start date: June 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus Apatinib in the treatment of advanced non-squamous NSCLC previously treated with first-line immunotherapy

NCT ID: NCT04325698 Terminated - Clinical trials for Advanced Non-squamous NSCLC

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Start date: June 11, 2020
Phase: Phase 3
Study type: Interventional

The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizimab sourced from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.

NCT ID: NCT03778853 Not yet recruiting - Clinical trials for Advanced Non-squamous NSCLC

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Start date: January 2019
Phase: Phase 4
Study type: Interventional

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.

NCT ID: NCT03768037 Recruiting - Clinical trials for Advanced Non-squamous NSCLC

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Start date: November 26, 2018
Phase: Phase 4
Study type: Interventional

Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.

NCT ID: NCT00369070 Terminated - Clinical trials for Advanced Non-squamous NSCLC

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Start date: January 31, 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with advanced non-squamous NSCLC.